Evotec SE (LON:0IRF)

Market Cap	1.10B
Revenue (ttm)	659.07M
Net Income (ttm)	-162.15M
Shares Out	n/a
EPS (ttm)	-0.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	116,049
Average Volume	43,016
Open	6.57
Previous Close	n/a
Day's Range	6.36 - 6.83
52-Week Range	4.06 - 17.76
Beta	1.09
RSI	63.20
Earnings Date	Apr 17, 2025

About Evotec SE

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, fibrosis, immunology, pain and inflammation, infectious, kidney, liver, rare, respiratory, fibrotic and metabolic disease; central nervous system (CNS) and cardio-metabolic disorders; and animal and women health. It ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 4,740
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IRF

Financial Performance

In 2024, Evotec SE's revenue was 796.97 million, an increase of 1.99% compared to the previous year's 781.43 million. Losses were -196.08 million, 133.7% more than in 2023.

Financial numbers in EUR